• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Antimicrobial Peptides Show Promise in Management of Atopic Dermatitis


Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Machado et al examined the current research on the use of antimicrobial peptides (AMPs) to manage atopic dermatitis (AD), describing the sources, benefits, and limitations of AMPs.1 With their potential to manage the skin microbiome, fight infections, and modulate the immune response, AMPs offer a promising option for treating AD.



AD is a result of genetic changes that create an immune response and disrupt the skin barrier, with the most common mutations being associated with filaggrin (FLG) production and tight junctions mutations and alterations. Other structural proteins that are downregulated in AD include desmogleins, desmocolins, involucrin, and keratins.

The FLG disruption interferes with the production of moisturizing factors in the skin’s stratum granulosum, disrupts lamellar body section, and halts the metabolic pathway partway through causing an absence of acidic metabolites. This causes an increase in the stratum corneum (SC) pH and enables higher proteolytic enzyme activity and a higher growth of Staphylococcus aureus.

The pathophysiology of AD involves considerations of the environmental area, the skin microbiome, the epidermal barrier, and the immune or inflammatory response. Naturally produced AMPs have an important role in maintaining a healthy skin microbiome “through modulation of the microbiota composition, proliferation and death, and, thus, also play a role in the metabolites produced by them.” These peptides display antibacterial activity and exert immunomodulatory effects.

Patients with atopic dermatitis are more likely to experience skin infections when AMP production is disrupted.

When AMP production is disrupted, patients with AD are more likely to experience skin infections from fungi, bacteria, and viruses. In patients with AD some AMPs, such as dermcidin and β-defensins, are underexpressed. Other AMPs, such as Rnase7, are overexpressed.

Recent research has focused on AMPs as an alternative to antimicrobials or as a pharmaceutical agent that can exert immunomodulatory activity. Natural and synthetic sources have been studied. Advantages of using AMPs include their ability to penetrate deeper skin layers, and “the fact that AMP-based treatment provides opportunities for interventions that closely resemble natural pathways and represent more of a replacement therapy than conventional treatment.”

Although some disadvantages to using AMPs have been reported, such as their rapid degradation by esterases or aminopeptidases, and their diminished stability in vivo, strategies to overcome these include penetration enhancers, encapsulation, and chemical modification to increase AMP permeability.

“[W]hile AMPs have already shown themselves to be natural and viable alternatives to conventional AD treatment regimens, and pharmacological solutions are already being explored and validated, there is still a way to go to enable AMPs to become cost-effective mainstream solutions for AD treatment,” Machado et al concluded.


  1. Machado M, Silva S, Costa EM. Are antimicrobial peptides a 21st-century solution for atopic dermatitis? Int J Mol Sci. 2023;24(17):13460. doi:10.3390/ijms241713460
Recent Videos
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Video 5 - featuring 2 panelists in, "Quality of Life + Closing Thoughts
© 2024 MJH Life Sciences

All rights reserved.